The purpose of this research is to determine how well patients respond to this combination treatment over a 12-month period. The medications work in different ways to target and destroy cancer cells – loncastuximab tesirine is an antibody-drug combination that delivers medication directly to cancer cells, while epcoritamab is a specialized antibody that helps the immune system recognize and fight cancer cells.

During the study, participants will receive both medications according to a specific schedule. Patients will have regular check-ups and imaging tests to monitor how their cancer responds to the treatment. The treatment period may last up to 54 weeks, depending on how well the patient responds and tolerates the medications. Throughout the study, doctors will closely monitor patients for any side effects or complications from the treatment.

The purpose of the study is to evaluate how well these treatments work together in patients whose lymphoma has returned or has not responded to previous treatments. Loncastuximab Tesirine is an antibody-drug conjugate, which means it is designed to deliver a drug directly to cancer cells, while Epcoritamab is a bispecific antibody that helps the immune system target and destroy cancer cells. The study will involve administering these treatments to participants and monitoring their response over a period of time, up to 12 months, to see if the cancer shrinks or disappears.

Participants in the study will receive the treatments through injections, with Loncastuximab Tesirine given intravenously (through a vein) and Epcoritamab given subcutaneously (under the skin). The study aims to determine the best overall response rate, which includes both complete and partial remissions, and will also look at other outcomes such as progression-free survival and overall survival. The study will help researchers understand the potential benefits and risks of this combination therapy for patients with these types of lymphoma.

The trial involves several medications, including Cytarabine, Tafasitamab (also known as MOR00208), Lenalidomide, Dexamethasone, Cisplatin, Bendamustine Hydrochloride, Polatuzumab Vedotin (also known as RO5541077), and Rituximab. These medications are used in various forms such as solutions for infusion, injections, and capsules. Some patients may receive a placebo as part of the study. The study will monitor the overall response rate to the second-line treatment and any significant side effects that may occur.

Participants in the study will undergo regular assessments, including blood tests to measure circulating tumor DNA and imaging tests like PET-CT scans to monitor disease progression. The study will also evaluate the quality of life of participants using a specific questionnaire. The trial is expected to continue until early 2026, with the goal of improving treatment strategies for patients with these types of lymphomas.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

Participants in the study will receive either tisagenlecleucel or one of the standard care treatments, which may include medications such as fludarabine, ifosfamide, cisplatin, melphalan, oxaliplatin, carmustine, ibrutinib, lenalidomide, gemcitabine hydrochloride, rituximab, cyclophosphamide, bendamustine hydrochloride, tocilizumab, cytarabine, dexamethasone acetate, etoposide, or carboplatin. Some participants may receive a placebo. The purpose of the study is to see if tisagenlecleucel can delay the progression of the disease or improve survival compared to the standard treatments.

The study will involve regular assessments to monitor the participants’ health and the effectiveness of the treatment. These assessments will include medical tests and evaluations to track the progression of the lymphoma and any side effects of the treatments. The study is expected to continue until 2026, with participants being closely monitored throughout the trial period to ensure their safety and to gather comprehensive data on the treatment’s impact.

Participants in the study will receive either the new treatment with Golcadomide or a placebo, along with the R-CHOP chemotherapy. The study will monitor the participants over a period to see how the cancer progresses and to check for any side effects. The main goal is to measure the time it takes for the cancer to worsen or for the patient to pass away, known as Progression-Free Survival (PFS). Other aspects being evaluated include overall survival, which is the time until death from any cause, and whether the cancer completely responds to the treatment.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new treatment or the placebo. This helps ensure the results are unbiased. The trial will continue until 2029, with recruitment starting in 2024. The findings from this study could provide valuable insights into the treatment of High-risk Large B-cell Lymphoma and potentially improve outcomes for patients with this type of cancer.

Participants in the study will receive either the combination of acalabrutinib with R-miniCHOP or R-miniCHOP alone. The study is designed for older adults who have not been treated for DLBCL before. The treatment will be administered over a period of time, with regular check-ups to monitor the patient’s health and the progression of the disease. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study aims to provide valuable information on whether the addition of acalabrutinib can improve outcomes for patients with DLBCL. The results will help doctors understand if this combination of treatments is more effective than the standard R-miniCHOP therapy. This research is important for developing better treatment options for patients with this type of lymphoma.

The purpose of the study is to see if adding Nivolumab after the initial treatment can improve the chances of the cancer not coming back within 12 months. Participants will first receive the DA-EPOCH-R treatment, which involves a series of medications given through an infusion into a vein, and Prednisolone taken as a tablet. This phase lasts for about 18 weeks. After completing this phase, patients will receive Nivolumab infusions for up to 52 weeks. Some participants may receive a placebo instead of Nivolumab to compare the outcomes.

The study will monitor the participants’ health and response to the treatment through regular check-ups and imaging tests like PET-CT scans, which help visualize the cancer’s activity in the body. The goal is to determine if the combination of treatments can increase the time patients remain free of cancer. This study is important for understanding how to better treat this aggressive form of lymphoma and improve patient outcomes.

The purpose of the study is to evaluate how well the combination of Glofitamab with the other drugs works compared to the standard treatment, which includes Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone. Participants in the study will receive one of these treatment combinations. The study will monitor the participants over a period to see how the cancer responds to the treatment and to check for any side effects. The study will also look at how long participants live without the cancer getting worse, which is known as progression-free survival.

Participants will be closely monitored throughout the study, which will include regular check-ups and tests to assess their health and the effectiveness of the treatment. The study is designed to provide valuable information on whether the new combination of drugs can offer better outcomes for patients with Large B-Cell Lymphoma compared to the existing standard treatment. This research could potentially lead to improved treatment options for individuals diagnosed with this type of lymphoma.